The People's Pharmacy

JUNE 12, 2023

The parties that benefit are the pharmaceutical companies and the pharmacies. The losers are patients, insurance companies and the country as a whole for wasting money on unneeded things. Medications are expensive, and some people throw them away after a year, even though they still might be good.

Labelling 62

Labelling Mail-Order Pharmacies Adverse Reactions FDA 62

The People's Pharmacy

MAY 8, 2023

The same was true of another of the company’s products, Delsam Pharma Artificial Eye Ointment , which the company voluntarily recalled shortly after. “The FDA said Global Pharma failed to use adequate, tamper-evident packaging and distributed the drugs without proper preservatives.” Here’s the kicker.

FDA 72

FDA Pharmaceutical Companies Pharmaceutical Companies Medical Schools 72

European Pharmaceutical Review

SEPTEMBER 2, 2022

This article explores just one aspect of the RMP, that of RMMs, and how their effectiveness is measured with Dr Sophie Jouaville, an associate principal at IQVIA working on the design and oversight of non-interventional real-world evidence (RWE) safety and health economics and outcomes research (HEOR) studies.

Adverse Reactions 76

Adverse Reactions Documentation Medical Schools Packaging 76

ISPE

OCTOBER 28, 2022

Pharmaceutical companies rely on AVI to overcome challenges associated with manual inspection, such as low inspection throughput and performance variations. Glass ampoules, as illustrated in Figure 1, offer protection against air and contaminations and are widely used as the primary packaging for pharmaceutical drugs.

Labelling 52

Labelling Pharmaceutical Companies Pharmaceutical Companies Packaging 52

Viseven

SEPTEMBER 14, 2023

For example, a pharmaceutical brand can face increased acquisition costs if a supplier has not delivered on time. It also bears extra replacement expenses when drugs are discarded due to improper packaging. Technologies allow pharmaceutical companies to collect and analyze a massive amount of data to ensure proper drug safety.

Packaging 52

Packaging Pharmaceutical Companies Pharmaceutical Companies Pharmacy Procurement 52

pharmaphorum

AUGUST 17, 2020

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. The post What can pharma marketing learn from other regulated industries? appeared first on.

Communication 91

Communication Insurance Packaging Pharmaceutical Companies 91

pharmaphorum

MAY 26, 2022

Within pharma and healthcare, where greater representation has been proven to lead to better health outcomes for all patients and the pharmaceutical companies developing medicines, change is also happening. As a Non-Clinical Assessor at MHRA he assessed non-clinical data packages for new and generic medicines. About the authors.

Packaging 141

Packaging Vaccines Generic Medicine Compounding 141

European Pharmaceutical Review

DECEMBER 21, 2022

All traditional small molecule pharmaceuticals include carbon building blocks – by definition, organic materials – which are then transformed via modern synthetic chemistry to assemble the complex and highly variable skeletons that the final target structures demand. However, it is already clear that the investments will be gargantuan.

Compounding 76

Compounding Pharmaceutical Companies Pharmaceutical Companies Packaging 76

ISPE

MARCH 7, 2023

This article reviews two case studies that cover sustainable pack types and extension of shelf life. Case Study One: Packaging Materials The first case study looks at developing more sustainable packaging materials and reducing the size of packaging materials. Let’s use the example of the packaging for medicines.

Packaging 52

Packaging Pharmaceutical Companies Pharmaceutical Companies Hospitals 52

ISPE

MAY 9, 2023

In an era when the world is accelerating the development of drugs and targeted medicines using innovative technologies, pharmaceutical companies still face registration hurdles for well-characterized molecules because of redundant or additional local regulatory requirements.

Documentation 52

Documentation Packaging Pharmaceutical Companies Pharmaceutical Companies 52

The Thyroid Pharmacist

OCTOBER 27, 2023

3] You can learn more about the HPA axis and adrenals here in the linked article. Follow package instructions. Follow package directions for each supplement. Doses of 300 mg are generally enough for everyday support, but you may wish to increase your dose for the situations listed above, per package instructions.

Health and Personal Care Stores 66

Health and Personal Care Stores Immunization Compounding Packaging 66

ISPE

MARCH 7, 2023

3 , 4 Most companies have some existing initiatives underway, but many do not yet have a fully comprehensive and integrated program. This article explores effective management and oversight processes for accelerated delivery of large-scale programs of work.

Health and Personal Care Stores 52

Health and Personal Care Stores Pharmaceutical Companies Pharmaceutical Companies Communication 52

ISPE

MARCH 6, 2023

link] A recent study published by My Green Lab 2 presented data from 74 biotechnology and pharmaceutical companies tracking the change in scope 1, 2, and 3 carbon intensity (measured in tons of CO2 emitted vs. the company’s revenue in USD) since 2015. For pharmaceutical companies, purchased goods (e.g.,

Packaging 52

Packaging Pharmaceutical Companies Pharmaceutical Companies Compounding 52

ISPE

JULY 6, 2023

This article provides a review on the current state of CM implementation, offers insights into life cycle management and regulatory aspects, and explains how a data- and knowledge-centric approach to risk management can help CM achieve its full potential. Even if regulators agree, the risk of a delay is enough to break a business case.

HIV Treatment and Prevention Agents 52

HIV Treatment and Prevention Agents Dosage Pharmaceutical Companies Pharmaceutical Companies 52

ISPE

SEPTEMBER 10, 2023

In this article, we describe the assessment of lag time for global regulatory approvals of postapproval CMC changes for multiple products over a three-year period. Consequently, comparing results across companies and through time will establish an increasingly robust perspective of trends in global approval durations.

Documentation 98

Documentation Process Improvement Packaging Pharmaceutical Companies 98